| Ytd | -3.51% | |
| 1y | -69.74% |
| Open | 3.40 | Prev Close | 3.39 | Low | 3.37 | High | 3.46 | Mkt Cap | 318.33M |
| Vol | 178.74K | Avg Vol | 1.25M | EPS | -0.46 | P/E | -7.47 | Forward P/E | -17.25 |
| Beta | 1.15 | Short Ratio | 10.82 | Inst. Own | 32.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-16 | 50-d Avg | 2.66 | 200-d Avg | 3.88 | 1yr Est | 35.47 |
AVXL News
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Dee
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the ana
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasd
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (N
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (N
Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD)
Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally admi
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral b
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp
US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur
This decision follows feedback from the European Medicines Agency's (EMA) Committee for Medicinal Pr
Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer's; EMA feedback prompts
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)
Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data ind
New study links early brain cleanup failure to Alzheimer's, supporting Anavex Life drug approach
Anavex highlighted a new peer-reviewed study published by University of California in Proceedings of
Findings underpin potential of Anavex' lead candidate blarcamesine through its upstream mechanism of
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber
Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzh
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, whic
Here is how Anavex Life Sciences (AVXL) and Cabaletta Bio, Inc. (CABA) have performed compared to th
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences Corp. (AVXL) Q1 2026 Earnings Call Transcript
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the ana
Company to host a webcast today at 8:30 am Eastern Time
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), today announc
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-st
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Retail investors are prepping for a lighter week of corporate earnings featuring Costco, MongoDB, Ul
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)